+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct-acting Antiviral Drug Market - Global Forecast 2026-2032- Product Image
Direct-acting Antiviral Drug Market - Global Forecast 2026-2032- Product Image
Sale

Direct-acting Antiviral Drug Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5311192
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Direct-acting Antiviral Drug Market is projected to reach USD 15.79 Billion in 2026. It is expected to continue growing at a CAGR of 14.10%, reaching USD 34.92 Billion by 2032.

Direct-acting antiviral drugs are reshaping viral disease management by targeting specific steps in viral replication rather than relying mainly on broad immune modulation. In hepatitis C virus care, modern DAA regimens have become the benchmark for precision antiviral therapy, with the World Health Organization reporting cure rates above 95% when patients receive appropriate treatment.

Market momentum is supported by a clear public health mandate. WHO estimates that about 50 million people were living with chronic hepatitis C infection in 2022, with approximately 1 million new infections occurring that year. This creates sustained demand for affordable oral regimens, simplified diagnostics, treatment decentralization, and procurement models that expand access beyond specialist centers.

Transformative Shifts in the DAA Landscape

The most important shift in the direct-acting antiviral drug landscape is the move from complex interferon-based therapy to short-course, all-oral, pan-genotypic regimens. This has reduced treatment duration, improved tolerability, and enabled broader use in primary care, correctional health, harm-reduction settings, and national elimination programs.

Competition is also shifting from clinical efficacy alone to access, adherence, and system-level execution. As patents expire and licensed generic supply expands in many low- and middle-income markets, manufacturers and public health buyers are increasingly focused on price sustainability, diagnostic linkage, resistance monitoring, and real-world treatment completion.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the DAA value chain through patient finding, clinical decision support, pharmacovigilance, and supply planning. AI-enabled risk stratification can help health systems identify undiagnosed hepatitis C among people with historical injection drug use, abnormal liver enzymes, dialysis exposure, incarceration history, or birth-cohort risk.

The cumulative impact is operational rather than speculative. AI can shorten the gap between screening and treatment initiation, forecast demand for national procurement, detect safety signals from real-world data, and support adherence interventions. However, industry leaders must pair AI deployment with validated datasets, privacy safeguards, explainable models, and clinical oversight to avoid bias in underserved populations.

Key Regional Insights for DAA Adoption

Asia-Pacific represents a high-priority region because of large patient pools, expanding generic availability, and government-backed hepatitis elimination initiatives. China, India, Japan, Australia, and South Korea are advancing screening and treatment pathways at different speeds, with India playing a central role in affordable active pharmaceutical ingredient and generic formulation supply. WHO’s Western Pacific and South-East Asia regional hepatitis strategies continue to emphasize diagnosis expansion, treatment scale-up, and integration of viral hepatitis services into primary care.

North America remains a high-value market driven by established reimbursement, advanced diagnostics, and strong specialist networks, although treatment gaps persist among uninsured populations, people who inject drugs, and incarcerated individuals. Latin America is improving access through public procurement and regional health programs, with Brazil and Mexico serving as important demand centers where national treatment guidelines and public-sector purchasing shape DAA availability.

Europe benefits from structured elimination strategies, centralized health systems, and mature clinical guidelines, but progress varies by country and by linkage-to-care capacity. The Middle East, particularly GCC markets, shows rising investment in specialty medicines and national screening supported by broader health transformation programs. Africa has the greatest access challenge, where disease burden, limited diagnostics, and financing constraints make low-cost regimens, simplified testing, and decentralized care essential to improve treatment coverage.

Key Group Insights Across Strategic Markets

ASEAN markets are characterized by diverse reimbursement systems, growing diagnostic capacity, and significant need for affordable pan-genotypic therapy, particularly where out-of-pocket costs and limited specialist coverage affect linkage to care. The GCC is positioned as a premium access cluster, supported by national health transformation programs, hospital modernization, and the ability to fund broad screening initiatives for viral hepatitis and related liver disease.

The European Union provides one of the most structured policy environments for DAA access, with strong regulatory oversight, established health technology assessment pathways, and cross-country evidence generation. BRICS countries combine high patient volumes with expanding domestic pharmaceutical capabilities, making them central to large-scale treatment access and generic competition. G7 countries continue to shape clinical standards, pharmacovigilance expectations, and premium innovation pathways, while NATO member states overlap with many high-income procurement systems that prioritize resilient medicine supply chains, continuity of essential therapies, and health security preparedness.

Key Country Insights for Commercial Strategy

The United States remains a commercially important DAA market, supported by advanced diagnostics and broad clinical expertise, but affordability, payer authorization, and underserved populations continue to shape treatment uptake. Canada emphasizes public health access and provincial reimbursement, while Mexico and Brazil are key Latin American markets where public procurement, national hepatitis programs, and public hospital networks influence demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature treatment pathways supported by specialist care networks, national guidelines, and established reimbursement processes, while Russia represents a large patient opportunity with access shaped by domestic policy, registration requirements, and procurement dynamics. China combines large disease prevalence with expanding local innovation and volume-based purchasing, while India is a major access market and global generic supplier. Japan, Australia, and South Korea are advanced markets with strong screening infrastructure, high clinical standards, and ongoing elimination priorities aligned with international viral hepatitis targets.

Actionable Recommendations for Industry Leaders

Industry leaders should align DAA strategy with the full care cascade: screening, confirmatory testing, treatment initiation, adherence, and post-treatment follow-up. The strongest opportunities will come from simplifying access in primary care, integrating treatment into harm-reduction programs, correctional health, and community clinics, and partnering with governments on hepatitis elimination targets.

Organizations should also strengthen real-world evidence programs, support affordable pricing models, and build supply resilience for active ingredients and finished-dose products. Digital patient navigation, AI-supported case finding, and collaboration with laboratories can reduce loss to follow-up and improve measurable cure outcomes. Leaders should prioritize ethical data use, pharmacovigilance readiness, and locally adapted access models to improve both clinical impact and long-term market relevance.

Research Methodology

This executive summary is developed using secondary research from authoritative public health, regulatory, clinical, and industry sources, including global disease burden updates, treatment guidelines, product approvals, procurement trends, and peer-reviewed evidence on DAA effectiveness.

The analysis triangulates epidemiology, access dynamics, regional policy signals, competitive behavior, and technology adoption to identify market direction. Insights are validated through consistency checks across public datasets, clinical guidance, regulatory information, and market-access evidence, with emphasis on verifiable trends rather than unsupported forecasts, market sizing, or market share estimates.

Conclusion

The direct-acting antiviral drug market is defined by a rare combination of high clinical efficacy, clear public health demand, and expanding access potential. With cure rates above 95% for appropriate hepatitis C treatment, DAAs remain one of the most impactful therapeutic classes in infectious disease and a critical tool for achieving viral hepatitis elimination objectives.

Future leadership will depend on more than product performance. Organizations that combine affordable access, evidence generation, AI-enabled patient identification, reliable supply, and region-specific partnerships will be best positioned to support elimination goals while sustaining long-term relevance in direct-acting antiviral therapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Direct-acting Antiviral Drug Market, by Product Type
7.1. Introduction
7.2. Branded Drugs
7.3. Generic Drugs
8. Direct-acting Antiviral Drug Market, by Therapeutic Area
8.1. Introduction
8.2. Hepatitis C Virus (HCV) Antivirals
8.2.1. NS5A Inhibitors
8.2.2. NS5B Polymerase Inhibitors
8.2.3. NS3/4A Protease Inhibitors
8.3. Hepatitis B Virus (HBV) Antivirals
8.3.1. Capsid Assembly Modulators
8.3.2. Entry Inhibitors
8.3.3. RNA Interference (RNAi)-Based Agents
8.4. HIV Direct-Acting Antivirals
8.4.1. Protease Inhibitors
8.4.2. Integrase Strand Transfer Inhibitors (INSTIs)
8.4.3. Reverse Transcriptase Inhibitors
8.5. Influenza & Respiratory Virus DAAs
9. Direct-acting Antiviral Drug Market, by Route of Administration
9.1. Introduction
9.2. Oral Direct-Acting Antivirals
9.3. Injectable DAAs
9.4. Intravenous DAAs
9.5. Long-Acting Depot Formulations
10. Direct-acting Antiviral Drug Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Clinics
11. Direct-acting Antiviral Drug Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. Direct-acting Antiviral Drug Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Direct-acting Antiviral Drug Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Direct-acting Antiviral Drug Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Beximco Pharmaceuticals Ltd.
16.3. Bristol-Myers Squibb Company
16.4. Cipla Limited
16.5. Dr. Reddy’s Laboratories Ltd.
16.6. Gilead Sciences, Inc.
16.7. GlaxoSmithKline plc
16.8. Hetero Labs Limited
16.9. Johnson & Johnson
16.10. Lupin Limited
16.11. Merck & Co., Inc.
16.12. Novartis AG
16.13. Pfizer Inc.
16.14. Regeneron Pharmaceuticals, Inc.
16.15. Roche Holding AG
16.16. Sun Pharmaceutical Industries Limited
16.17. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS C VIRUS (HCV) ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS C VIRUS (HCV) ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HEPATITIS C VIRUS (HCV) ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NS5A INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NS5A INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NS5A INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS B VIRUS (HBV) ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS B VIRUS (HBV) ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS B VIRUS (HBV) ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CAPSID ASSEMBLY MODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CAPSID ASSEMBLY MODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CAPSID ASSEMBLY MODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RNA INTERFERENCE (RNAI)-BASED AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RNA INTERFERENCE (RNAI)-BASED AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL RNA INTERFERENCE (RNAI)-BASED AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HIV DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL HIV DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL HIV DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INFLUENZA & RESPIRATORY VIRUS DAAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INFLUENZA & RESPIRATORY VIRUS DAAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INFLUENZA & RESPIRATORY VIRUS DAAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INJECTABLE DAAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTABLE DAAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INJECTABLE DAAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS DAAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS DAAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAVENOUS DAAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LONG-ACTING DEPOT FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL LONG-ACTING DEPOT FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LONG-ACTING DEPOT FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 110. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 111. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 112. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 114. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 115. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 128. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 129. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 130. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 131. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 132. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 138. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 139. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 140. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 141. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 142. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 143. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 147. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 148. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 149. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 150. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 151. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 152. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 165. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 166. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 167. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 168. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 169. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 174. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 175. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 176. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 177. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 178. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 183. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 184. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 185. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 186. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 187. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 202. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 203. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 204. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 205. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 206. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 211. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 212. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 213. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 214. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 215. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 219. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 220. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 221. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 222. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 223. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 224. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 238. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 239. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 240. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 241. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 242. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 248. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 249. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 250. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 251. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 257. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 258. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 265. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 266. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 267. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 268. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 269. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 274. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 275. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 276. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 277. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 278. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 283. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 284. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 285. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 286. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 287. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 288. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 292. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 293. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 294. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 295. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 296. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 297. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 301. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 302. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 303. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 304. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 305. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 308. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 310. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 311. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 312. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 313. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRAT

Companies Mentioned

  • AbbVie Inc.
  • Beximco Pharmaceuticals Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Limited
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 15.79 Billion
Forecasted Market Value ( USD ) by 2032 $ 34.92 Billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Antiviral Drugs Market - Global Forecast 2026-2032 - Product Image

Antiviral Drugs Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Antiviral Therapeutics Market - Global Forecast 2026-2032 - Product Image

Antiviral Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Antivirals Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antivirals Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Direct Acting Antiviral Drug Market

Direct-acting antiviral drugs (DAAs) represent a class of pharmaceuticals specifically targeting viruses at the molecular level to prevent their proliferation. Within the broader category of infectious diseases drugs, DAAs are used mainly for the treatment of viral infections such as hepatitis C and can have a transformative effect by providing high cure rates and shortened treatment durations compared to older interferon-based therapies. These drugs act directly on viral enzymes and proteins critical to the viral life cycle, disrupting processes such as viral RNA replication and protein production. Their development has been a major advance in the therapeutic management of chronic viral infections, leading to substantial improvements in patient outcomes. The DAA market is characterized by innovation and rapid development of new therapies that offer improved efficacy and safety profiles. Key players in the direct-acting antiviral drug market include Gilead Sciences, Merck & Co., AbbVie Inc., and Bristol-Myers Squibb. Gilead Sciences, for example, is known for its portfolio of DAAs for the treatment of hepatitis C, which has redefined the standard of care in this therapeutic area. These companies are continuously engaged in the research and development of new DAAs that promise to enhance patient care and expand therapeutic options for various viral infections. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.